Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$271.71 USD

271.71
847,461

-0.89 (-0.33%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $271.82 +0.11 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

QIAGEN's Coronavirus Test Kit Development Gets BARDA Funding

by Zacks Equity Research

QIAGEN (QGEN) receives support from the government to accelerate the development of the QIAstat-Dx test kit to detect the coronavirus causing virus.

Zacks Equity Research

Walgreens Adopts New Measures to Fight Against Coronavirus

by Zacks Equity Research

Walgreens (WBA) collaborates with industry partners and healthcare administrators to provide greater access to government-run COVID-19 testing facilities.

Zacks Equity Research

National Vision Grows on Positive Comps, Rising Costs a Woe

by Zacks Equity Research

National Vision's (EYE) positive comparable store sales (comps) growth story continues for 72 consecutive quarters.

Zacks Equity Research

Bio-Rad Launches SARS CoV-2 Standard for Coronavirus Testing

by Zacks Equity Research

With the launch of Bio-Rad's (BIO) SARS CoV-2 Standard, it aims to help laboratories validate coronavirus testing and accelerate the access to testing.

Zacks Equity Research

Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strong domestic and international results for the fourth quarter of 2019.

Zacks Equity Research

Zimmer Biomet Grows on Strong Emerging Market, Innovation

by Zacks Equity Research

Zimmer Biomet (ZBH) solidifies its foothold in the emerging markets on strong operational and sales performance.

Zacks Equity Research

OrthoPediatrics Announces Latest Screw System Launch in US

by Zacks Equity Research

OrthoPediatrics (KIDS) releases the latest cannulated screw system as part of its beta release to address trauma as well as other bone fixation procedures.

Zacks Equity Research

CVS Health's Schnuck Pharmacy Buyout to Widen Specialty Arm

by Zacks Equity Research

Given the growing prospects of specialty pharmacy, CVS Health (CVS) is prioritizing expansion of this business.

Zacks Equity Research

ResMed (RMD) Grows on SaaS Capabilities Amid Rising Expenses

by Zacks Equity Research

Within SaaS, ResMed (RMD) registers growing momentum in the Brightree service portfolio.

Zacks Equity Research

Here's Why You Should Add ResMed (RMD) in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) on its strong segmental and international results for the fiscal second quarter.

Zacks Equity Research

Henry Schein (HSIC) Expands by Signing JV With Casa Schmidt

by Zacks Equity Research

Henry Schein (HSIC) strengthens position in Spain and Portugal by signing a JV with Casa Schmidt.

Zacks Equity Research

Quest Diagnostics (DGX) to Launch Coronavirus Test Service

by Zacks Equity Research

Quest Diagnostics (DGX) aims to mobilize effective public health response to the coronavirus outbreak through quality laboratory testing.

Zacks Equity Research

Zacks.com featured highlights include: Microsoft, ResMed, Maxim Integrated Products and Signature Bank

by Zacks Equity Research

Zacks.com featured highlights include: Microsoft, ResMed, Maxim Integrated Products and Signature Bank

Zacks Equity Research

Steady Global Growth, Product Launches Aid Hill-Rom Business

by Zacks Equity Research

Hill-Rom (HRC) holds an encouraging 2022 outlook in terms of product launches.

Zacks Equity Research

Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher (TMO) on the strong Q4 performance in the majority of its segments.

Zacks Equity Research

4 GARP Stocks to Scoop Up for Maximum Returns

by Zacks Equity Research

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

Benjamin Rains headshot

Coronavirus Volatility, Fed's Next Move & Buy this Soaring Medical Stock - Free Lunch

by Benjamin Rains

Thursday's market downturn continues coronavirus volatility. What the Fed might do next. What's going on with stocks such as United Airlines, Kroger, and Netflix. The episode then closes with a look at why ResMed is a Zacks Rank #1 (Strong Buy) stock...

Zacks Equity Research

Is ResMed (RMD) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (RMD) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Here's Why You Should Hold on to Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Omnicell (OMCL) on its strong segmental performance in Q4.

Zacks Equity Research

Here's Why You Should Retain Henry Schein (HSIC) Stock Now

by Zacks Equity Research

Investor confidence continues to be high in Henry Schein (HSIC) stock, courtesy of solid prospects.

Zacks Equity Research

Intersect ENT Down on Low Propel Sales, Pricing Pressure

by Zacks Equity Research

Intersect ENT (XENT) registers dull Propel performance on poor unit sales in Q4.

Zacks Equity Research

Luminex Hits a New 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Luminex (LMNX) has been gaining from several recent positive developments.

Zacks Equity Research

Thermo Fisher (TMO) to Buy Molecular Diagnostics Major QIAGEN

by Zacks Equity Research

Thermo Fisher (TMO) expects QIAGEN's strong molecular diagnostics presence to complement its specialty diagnostics capabilities.

Zacks Equity Research

National Vision (EYE) Rides on Robust Growth Across All Lines

by Zacks Equity Research

National Vision (EYE) continues to register strong segmental performances.

Zacks Equity Research

Here's Why You Should Hold on to Align Technology for Now

by Zacks Equity Research

Investors continue to be optimistic about Align Technology (ALGN) on its strong segmental performance in Q4.